Biotech group Genentech scored a big victory as the U.S. Food and Drug Administration has granted a priority review of the company’s newest cancer-treating drug, Tecentriq.
The new drug is designed for people in advance stages of bladder cancer who are unable to go through chemotherapy or cannot have it removed by means of surgery. It is also used in cases where the disease has progressed substantially over a 12-month period.
“Tecentriq became the first treatment approved by the FDA for people with previously treated advanced bladder cancer in more than 30 years,” Dr. Sandra Homing, chief medical officer and head of global product development at Genentech, said. “We are committed to continue working with the FDA to make Tecentriq available to more people with this type of cancer, specifically those that are unable to tolerate chemotherapy.”
A priority review, according to a news release from Genentech, has resulted from the FDA seeing significant results from patients suffering from the targeted disease who took the drug.
Genentech was granted a priority review after having a Biologics License Application approved by the FDA. The FDA will determine whether to grant final approval by April 30.
FDA approves review of Genentech drug to treat advanced bladder cancer
Alerts Sign-up